This is the authors' abstract. We don't add key points for this paper.
Retinitis pigmentosa (RP) is a genetically heterogeneous group of inherited retinal dystrophies for which broadly applicable therapies remain limited. Current gene-specific strategies fail to address the diverse genetic landscape of the disease. This study applies an integrated network medicine pipeline to identify convergent disease mechanisms and nominate mutation-agnostic, repurposable therapeutics. We curated 125 RP-associated genes from Online Mendelian Inheritance in Man (OMIM) and DisGeNET to construct distinct disease modules within the human protein–protein interactome using the multi-Steiner trees (MuST) and DIseAse MOdule Detection (DIAMOnD) algorithms via the NeDRex platform. To capture dynamic disease states, we integrated transcriptomic profiles from PRPF31 and RP2 patient-derived retinal organoids using the network-constrained biclustering algorithm (BiCoN). Finally, we prioritized Food and Drug Administration-approved drugs targeting these conserved modules, using the network proximity and closeness centrality algorithms. Genomic analysis revealed a highly interconnected module enriched for messenger RNA splicing and cilium assembly. Transcriptomic integration uncovered mutation-specific stress signatures: PRPF31 organoids exhibited aberrant cell cycle re-entry and intracellular trafficking defects, while RP2 organoids displayed genomic instability driving premature senescence and a viral-mimicking inflammatory response. Integrative drug prioritization identified actionable candidates, including the spleen tyrosine kinase (SYK) inhibitor fostamatinib and the histone deacetylase inhibitor valproic acid, which target these shared downstream pathogenic hubs. Our multi-scale approach successfully bridges genetic heterogeneity in RP by mapping convergent pathways of photoreceptor death. We provide a mechanistically grounded shortlist of repurposable drug candidates for experimental validation, offering a data-driven strategy to develop broad-spectrum therapies for RP.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Agarwal et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: